These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease. Ahamad S; Bhat SA J Med Chem; 2022 Dec; 65(24):15993-16032. PubMed ID: 36490325 [TBL] [Abstract][Full Text] [Related]
4. Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. Kinnunen KM; Mullin AP; Pustina D; Turner EC; Burton J; Gordon MF; Scahill RI; Gantman EC; Noble S; Romero K; Georgiou-Karistianis N; Schwarz AJ Front Neurol; 2021; 12():712565. PubMed ID: 34744964 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis. Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J Elife; 2021 Apr; 10():. PubMed ID: 33871358 [TBL] [Abstract][Full Text] [Related]
6. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease. Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099 [TBL] [Abstract][Full Text] [Related]
7. Foundation-directed therapeutic development in Huntington's disease. Dominguez C; Munoz-Sanjuan I J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836 [TBL] [Abstract][Full Text] [Related]
9. Clinical Features of Huntington's Disease. Ghosh R; Tabrizi SJ Adv Exp Med Biol; 2018; 1049():1-28. PubMed ID: 29427096 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of Huntington's disease: Molecular and clinical approaches. Kumar D; Hasan GM; Islam A; Hassan MI Biochem Biophys Res Commun; 2023 May; 655():18-24. PubMed ID: 36913762 [TBL] [Abstract][Full Text] [Related]
11. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566 [TBL] [Abstract][Full Text] [Related]
12. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease. Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248 [TBL] [Abstract][Full Text] [Related]
13. Lowering Mutant Huntingtin Levels and Toxicity: Autophagy-Endolysosome Pathways in Huntington's Disease. Valionyte E; Yang Y; Roberts SL; Kelly J; Lu B; Luo S J Mol Biol; 2020 Apr; 432(8):2673-2691. PubMed ID: 31786267 [TBL] [Abstract][Full Text] [Related]
14. Huntington's Disease: New Frontiers in Therapeutics. Pan L; Feigin A Curr Neurol Neurosci Rep; 2021 Feb; 21(3):10. PubMed ID: 33586075 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. Dash D; Mestre TA Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582 [TBL] [Abstract][Full Text] [Related]
16. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy. Chang R; Liu X; Li S; Li XJ Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812 [TBL] [Abstract][Full Text] [Related]
17. Analysis of mutant and total huntingtin expression in Huntington's disease murine models. Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120 [TBL] [Abstract][Full Text] [Related]
18. Translating Antisense Technology into a Treatment for Huntington's Disease. Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033 [TBL] [Abstract][Full Text] [Related]